loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

FDC Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
FDC Ltd. 29 May 2025 17:48 PM
Result PDF

Q4FY25 & FY25 Result Announced for FDC Ltd.

Pharmaceuticals company FDC announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Operating Revenue increased by 6.5%, from Rs 462 crore to Rs 492 crore.
  • EBITDA declined by 4.2%, from Rs 56 crore to Rs 54 crore.
  • EBITDA Margin dropped from 12.2% to 11.0%.
  • PBT (Profit Before Tax) fell 18.3%, from Rs 65 crore to Rs 53 crore.
  • PAT (Profit After Tax) declined 16.5%, from Rs 46 crore to Rs 39 crore.
  • EPS decreased 16.5%, from Rs 2.84 to Rs 2.38.

FY25 Financial Highlights:

  • Operating Revenue rose by 8.5%, from Rs 1,943 crore to Rs 2,108 crore.
  • EBITDA declined by 4.1%, from Rs 339 crore to Rs 325 crore.
  • EBITDA Margin reduced from 17.4% to 15.4%.
  • PBT declined by 9.8%, from Rs 396 crore to Rs 357 crore.
  • PAT dropped by 12.5%, from Rs 305 crore to Rs 267 crore.
  • EPS fell by 11.8%, from Rs 18.58 to Rs 16.39.

Management Commentary

We’re pleased to share that your Company crossed the 22,000 crore revenue mark in FY25, growing 8.5% to reach 32,108 crore. This milestone reflects the continued strength of our India Formulations business, which contributed 84% of sales and growing with 14.4% YoY, and strong momentum in our API segment, which grew 21.1% YoY. Export Formulation business however reported decline of 25.6% YoY primarily due to lower sales in US market and few of the ROW markets. Lower sales in US market were majorly due to regulatory issues. The regulatory issues of US market have now been addressed, and management believe the business should be back in its normal flow in the coming financial year.

Profitability during the year was impacted primarily due to drop in the Export formulation business, reduction in price of Electral due to NLEM price revision announcement during QI1FY25, and higher employee costs in view of moderate expansion in field force in certain clusters of India market.

Result PDF

Result PDF

Pharmaceuticals company FDC announced Q3FY25 results

  • Operating Revenue for Q3FY25 stood at Rs 464 crore, registering a 1.3% YoY growth from Rs 458 crore in Q3FY24.
  • EBITDA for Q3FY25 stood at Rs 47 crore, down 44.3% YoY from Rs 84 crore.
  • EBITDA Margin contracted to 10.1% from 18.3% YoY.
  • Profit Before Tax (PBT) declined 47.5% YoY to Rs 51 crore, compared to Rs 98 crore.
  • Profit After Tax (PAT) dropped 53.2% YoY to Rs 37 crore from Rs 79 crore.
  • Earnings Per Share (EPS) decreased 53.2% YoY to Rs 2.28, compared to Rs 4.86.

Management Commentary:

The company delivered revenue growth of 9.1% in 9MFY25, driven by robust performance across all business segments, except for US Formulations. The export formulations business witnessed a 20.7% YoY decline in 9MFY25, primarily due to lower sales in the US market. On the other hand, the API business demonstrated strong momentum, recording a 25.6% YoY growth in Q3FY25 and 25.1% YoY growth in 9MFY25.

EBITDA for Q3FY25 and 9MFY25 was impacted by lower sales in export formulation business, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher employee costs.

Result PDF

Pharmaceuticals company FDC announced Q4FY24 & FY24 results:

Operating Revenue

FDC Limited reported an increase in operating revenue, with a 6.3% growth in the fourth quarter (Q4FY24) and an 8.9% growth for the full fiscal year (FY24) compared to the previous corresponding periods.

EBITDAs and Profitability

The company's EBITDA grew significantly, with an increase of 15.1% for Q4 and 34.9% for the full year. Profit after tax (PAT) for Q4FY24 was reported at Rs 46 crore, showing a growth of 50.9%, and Rs 305 crore for FY24, marking an increase of 57.4% year-over-year.

Earnings Per Share (EPS)

Earnings Per Share saw a substantial rise for both Q4FY24 and FY24, increasing by 53.7% and 59.3% respectively, indicating a strong performance by the company.

Business-wise Sales Breakdown

Domestic formulations showed growth, particularly driven by flagship brands such as Electral, Zifi, Enerzal, and Zifi-O.

US and Emerging Markets formulating businesses are also trending positively, although US formulations saw a slight decrease in the fourth quarter.

API sales exhibited a significant growth of 24.0% for the fourth quarter and an 11.9% increase for the fiscal year.

Geographical Revenue Contributions

Revenue from international operations, specifically in the US and Rest of the World (ROW) markets, has been notable, with consolidated revenue showing a 12% increase. The export formulations accounted for 15% of the total consolidated revenue.

Result PDF

Pharmaceuticals company FDC announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Operating Revenue: Rs 486 crore, a solid 9.3% YoY growth.
    • EBITDA: Rs 76 crore, up by 13.5% YoY.
    • EBITDA Margin: 15.2%.
    • PBT: Rs 93 crore, a notable 34.3% YoY increase.
    • PAT: Rs 70 crore, showing a strong 34.7% YoY growth.
    • EPS: Rs 4.22, with a significant 36.2% YoY increase.
  • H1FY24:
    • Operating Revenue: Rs 1,023 crore, an 8.8% YoY growth.
    • EBITDA: Rs 198 crore, a substantial 36.5% YoY increase.
    • EBITDA Margin: 19.4%.
    • PBT: Rs 233 crore, with a remarkable 49.6% YoY growth.
    • PAT: Rs 180 crore, showing a notable 46.7% YoY increase.
    • EPS: Rs 10.84, with a strong 47.5% YoY growth.

Commenting on the results, the company said, "During Q2FY24 and H1FY24, we are pleased to announce that we have achieved growth across all our business segments in Domestic as well as International business. The major driver growth in the Domestic Formulation business is laid by the flagship brands, Electral, Zifi, Enerzal and Zifi-O. Growth in the International Formulation business is primarily laid by the US market growing by 31.7% during H1FY24. Further, the margins and profitability have shown significant improvements during the quarter as well as H1FY24 attributable primarily to improved sale realisation, lower cost of goods sold, and lower operating expenses."

 

 

Result PDF

Pharmaceuticals company FDC announced Q1FY24 results:

  • Operating revenue of Rs 536 crore in Q1FY24 compared to Rs 495 crore in Q1FY23, up 8.4% YoY
  • EBITDA of Rs 122 crore in Q1FY24 compared to Rs 78 crore in Q1FY23, up 56.4% YoY
  • EBITDA% of 22.7% in Q1FY24 compared to 15.8% in Q1FY23
  • PBT of Rs 141 crore in Q1FY24 compared to Rs 87 crore in Q1FY23, up 61.7% YoY
  • PAT of Rs 110 crore in Q1FY24 compared to Rs 71 crore in Q1FY23, up 55.4% YoY
  • EPS of Rs 6.62 in Q1FY24 compared to Rs 4.23 in Q1FY23, up 56.6% YoY

Commenting on the results, management said, "We are pleased to announce that we have achieved growth across all our business segments in the current quarter. Our domestic business segment reported growth of 6% during the quarter, albeit under some price pressure. Notably, our Export Formulation and API business segments exhibited robust YoY growth of 19%.

Furthermore, we are delighted to report that our margins and profits have shown improvement which is attributed due to improved sales realization and an increase in other income. We remain focused on sustaining and building upon these advancements in the upcoming periods."

 

 

Result PDF

Pharmaceutical firm FDC announced Q3FY23 results:

  • Consolidated Q3FY23 and 9MFY23:
    • India Market:
      • The sale of branded formulations in India for Q3FY23 was Rs 318 crore, with a growth of 10.2% on YoY and -14.1% on QoQ.
      • Overall sales in the Indian market accounted for 78% of total consolidated sales for the quarter.
      • For 9MFY23 sales were at Rs 1,109 crore, growth of 8.1% over the same period last year.
      • As per secondary sales data by IQVIA for the quarter that ended Dec 31, 2022, the company delivered strong YoY growth of 17.5% compared to the Indian Pharmaceutical Market (IPM) growth of 10.0% YoY.
    • Export Formulations Market:
      • Formulation sales in the export market were Rs 72 crore in Q3FY23, up by 84.2% over YoY and up by 24.6% over QoQ, accounting for 17% of total consolidated sales.
      • For 9MFY23 sales were Rs 185 crore, up by 55.3% over the same period last year. The main contributor is the USA market, accounting for 47% of total export formulations sales.
    • Export API Market:
      • API sales in the export market were Rs 20 crore in Q3FY23, up by 37.4% over YoY and accounted for 5% of total consolidated sales. For the 9MFY23, sales were Rs 55 crore, up by 31% over the same period last year.

 

 

Result PDF

Pharmaceuticals firm FDC Announced Q1FY23 Result :

  • The sale of branded formulations in India for Q1FY23 was Rs. 421.03 crores, with a growth of 8% on YoY and 52% on QoQ. Overall sales in the Indian market accounted for 85% of total consolidated sales for the quarter.
  • As per secondary sales data by IQVIA for the quarter ended June 30, 2022, the Company delivered strong YoY growth of 21.6% compared to the Indian Pharmaceutical Market (IPM) growth of 17.2% YoY. This growth was mainly driven by Big brands like Zifi, Electral and Enerzal which witnessed a good volume growth. Electral has moved up to 34th in IPM in MAT Jun'22 as compared to 37th in the same period last year.
  • Export Formulations Market:
    • Formulation Sales in the Export market were Rs. 54.56 crores in Q1FY23, up by 26.5% over YoY and up by 15% over QoQ and accounted for 11% of total consolidated sales. The main contributor is the USA market, accounting for 52% of total Export Formulations Sales.
    • ANDA is filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%.
    • API Sales in the Export market were Rs. 17.37 crores in QIFY23, up by 25% over YoY and up by 21% over QoQ and accounted for 4% of total consolidated sales.

 

Result PDF

Pharmaceuticals compay FDC declares Q4FY22 result:

  • Q4FY22 revenue at Rs. 278.38 Crore, up 18% YoY
  • FY22 revenue at Rs. 1,304.44 Crore, up 31% YoY
  • As per secondary sales data by IQVIA for the period MAT Mar'22, the Company delivered a strong YoY growth of 19% compared to Indian Pharmaceutical Market (IPM) growth of 18% YoY. This growth was mainly driven by Big brands like Ziti, Electral, Enerzal and Zathrin which witnessed a good volume growth.
  • FDC has moved one rank up from 23rd in MAT Mar'21 to 22nd in MAT Mar'22 in IPM. On MAT Mar'22, Ziti's rank has moved to 39th largest brand in IPM from 53rd in the same period last year while Electral has moved up to 40th in IPM from 43rd in the same period last year.
  • Export Formulations Market:
    • Q4FY22 revenue at Rs. 47.28 Crores, down 17% YoY
    • FY22 revenue at Rs. 163.27 Crores, down 39% YoY
    • We have received registration for Electral in several countries, this is in line with our efforts of making Electral a global brand across territories.
    • Q4FY22 revenue at Rs.14.35 Crores, down 24% YoY
    • FY22 revenue at Rs. 55.95 Crores, down 8% YoY

 

 

Result PDF

Pharmaceuticals company FDC announced Q3FY22 results:

  • Q3FY22 revenue at Rs. 288.42 Crore, up 15% YoY
  • 9MFY22 revenue at Rs.1,026.06 Crore, up 35% YoY
  • Overall sales in India markets accounted for 85% of total consolidated sales for the quarter.

Commenting on the results;

"We saw good growth in our Domestic business, which is a big pie of our overall business. This was driven by robust demand across our established therapies and brands leading to 35 % revenue growth. Our USA business portfolio saw some price erosion and lower demand for current portfolio laid by re-entry of competitors, still our partner has been successful in maintaining good portion of market share."

Result PDF

Trending News

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

L&T's Buildings & Factories (B&F) business has won multiple large domestic EPC orders across tourism

Published on 18-Dec-2025 09:03

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Marico has amended the definitive agreements to extend the timeline for acquiring the remaining 40% stake in Satiya Nutraceuticals (PLIX) by 12 months

Published on 18-Dec-2025 09:01

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Axis Bank MD & CEO Amitabh Chaudhry said that recent RBI rate cuts will delay stabilisation of net interest margins

Published on 18-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status